The Anti-F3/Factor III/Tissue Factor/CD142 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the F3 protein, also known as Factor III, Tissue Factor, or CD142, which plays a critical role in the initiation of blood coagulation. The antibody is comprised of a human IgG4 subclass heavy chain with an SP variant and a human kappa light chain. It exhibits a predicted molecular weight of approximately 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG4 kappa. This product is essential for research in hematology, particularly in studies involving coagulation pathways and cardiovascular disease mechanisms.
The Anti-F3/Factor III/Tissue Factor/CD142 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. This antibody specifically targets the F3 protein, also known as Factor III, Tissue Factor, or CD142, which plays a critical role in the initiation of blood coagulation. The antibody is comprised of a human IgG4 subclass heavy chain with an SP variant and a human kappa light chain. It exhibits a predicted molecular weight of approximately 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG4 kappa. This product is essential for research in hematology, particularly in studies involving coagulation pathways and cardiovascular disease mechanisms.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
Please check COA/MSDS for correct molecular weight.
Calculate the dilution required to prepare a stock solution.This equation is commonly abbreviated as: C1V1 = C2V2
Frequently Asked Questions
What are Biosimilar Antibodies?
Biosimilar antibodies are research-grade recombinant antibodies designed to closely resemble approved therapeutic antibodies in terms of amino acid sequence, structural characteristics, and biological activity. These antibodies are generated using recombinant expression technologies and retain the same variable regions as their corresponding reference therapeutics, thereby preserving target specificity and binding affinity. Owing to these properties, biosimilar antibodies serve as reliable and cost-effective research reagents for applications in drug discovery, pharmacological studies, and basic biomedical research.
Research-grade biosimilar antibodies have been successfully expressed and functionally validated against a wide range of widely studied targets. These antibodies can be directly utilized as positive control reagents in drug discovery programs, as well as reference tools for rapid verification of the biological functions of target proteins in biochemical and cellular assays.
